立体定向放射外科治疗脑室内脑膜瘤:系统综述与Meta分析
该系统综述与Meta分析纳入14项研究(其中7项可合并),评估立体定向放射外科治疗脑室内脑膜瘤的肿瘤控制与并发症。原发脑室内脑膜瘤肿瘤控制比例为0.92(95%CI 0.69-0.98),原发与辅助病例总体控制为0.87(95%CI 0.34-0.99),2年无进展生存率为94.70%,原发较辅助无进展生存更优(P<0.01)。
要点
- 原发脑室内脑膜瘤SRS后肿瘤控制比例为0.92(95%CI 0.69-0.98),异质性不显著(P=0.73)。
- 原发与辅助病例总体肿瘤控制比例为0.87(95%CI 0.34-0.99),异质性不显著(P=0.92)。
- SRS后瘤周水肿发生16/71例(0.16;95%CI 0.03-0.56),异质性不显著(P=0.32)。
核心结论
- 作者认为,无论是否接受过先前治疗,脑室内脑膜瘤患者接受SRS可获得高肿瘤控制率和低并发症风险。
- 作者指出,SRS可能成为无症状脑室内脑膜瘤有前景的一线治疗选择,但其在有症状患者中的疗效及与切除术的比较需进一步研究。
研究设计与样本
- 系统检索Scopus、Web of Science、PubMed和Embase截至2023年6月5日的文献,由两名独立作者筛选与提取数据。
- 共纳入14项研究,其中仅7项有足够数据用于Meta分析;采用随机效应Meta分析评估肿瘤控制比例,并基于个体患者数据进行无进展生存的Meta分析。
主要发现
- 原发脑室内脑膜瘤接受SRS的患者肿瘤控制比例为0.92(95%CI 0.69-0.98),异质性不显著(P=0.73)。
- 原发与辅助病例的总体肿瘤控制比例为0.87(95%CI 0.34-0.99),异质性不显著(P=0.92)。
- SRS后瘤周水肿发生于71例中的16例(0.16;95%CI 0.03-0.56),异质性不显著(P=0.32)。
- 个体患者数据Meta分析显示2年随访无进展生存率为94.70%。
- Log-rank检验显示原发SRS较辅助SRS的无进展生存更优(P<0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intraventricular meningioma (IVM) is a rare subtype of intracranial meningioma, accounting for 9.8 to 14% of all intraventricular tumors. Currently, there is no clear consensus on which patients with IVM should receive conservative treatment, surgery, or stereotactic radiosurgery (SRS). This research aims to analyze the outcomes, including survival and recurrence rates of patients who undergo SRS for IVM as a primary or adjuvant treatment. METHODS: A systematic search was conducted in Scopus, Web of Science, PubMed, and Embase till June 5th 2023. Screening and data extraction were performed by two independent authors. Random-effect meta-analysis was performed to determine the tumor control proportion of IVM cases treated with SRS. Individual patient data (IPD) meta-analysis was performed for the progression-free survival (PFS) of the patients in the follow-up time. All analyses were performed using the R programming language. RESULTS: Out of the overall 132 records, 14 were included in our study, of which only 7 had enough data for the meta-analysis. The tumor control proportion was 0.92 (95% CI, 0.69-0.98) in patients who underwent SRS for primary IVM. The overall tumor control in both primary and adjuvant cases was 0.87 (95% CI, 0.34-0.99). the heterogeneity was not significant in both meta-analyses (P = 0.73 and P = 0.92, respectively). Post-SRS perifocal edema occurred in 16 out of 71 cases (0.16; 95% CI, 0.03-0.56), with no significant heterogeneity (P = 0.32). IPD meta-analysis showed a PFS of 94.70% in a 2-year follow-up. Log-rank test showed better PFS in primary SRS compared to adjuvant SRS (P < 0.01). CONCLUSIONS: According to this study, patients with IVM can achieve high rates of tumor control with a low risk of complications when treated with SRS, regardless of whether they have received prior treatment. Although SRS could be a promising first-line treatment option for asymptomatic IVM, its efficacy in symptomatic patients and its comparison with resection require further investigation.
引用
- Khaboushan AS, Ohadi MAD, Amani H, et al. Stereotactic radiosurgery for intraventricular meningioma: a systematic review and meta-analysis. Acta Neurochir (Wien). 2024. PMID: 38980438. doi:10.1007/s00701-024-06185-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。